(LH) Laboratory of America - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US5049221055
Stock: Medical Testing, Drug Development, Health Services
Total Rating 49
Risk 89
Buy Signal -0.52
| Risk 5d forecast | |
|---|---|
| Volatility | 23.9% |
| Relative Tail Risk | -4.20% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.39 |
| Alpha | -3.49 |
| Character TTM | |
|---|---|
| Beta | 0.452 |
| Beta Downside | 0.346 |
| Drawdowns 3y | |
|---|---|
| Max DD | 17.36% |
| CAGR/Max DD | 0.78 |
EPS (Earnings per Share)
Revenue
Description: LH Laboratory of America March 04, 2026
Labcorp Holdings Inc. (LH) provides diagnostic and biopharmaceutical laboratory services. The companys Diagnostics Laboratories segment offers a wide range of medical tests, including blood chemistry, infectious disease panels, and genetic testing. This segment operates within the clinical laboratory industry, which processes millions of tests daily for patient diagnosis and monitoring.
The Biopharma Laboratory Services segment supports drug and medical device development. This includes clinical trial testing and companion diagnostic development, critical components of the pharmaceutical research and development pipeline. Labcorp serves a diverse client base, including pharmaceutical companies, healthcare providers, and managed care organizations.
Labcorp also provides digital tools for patients and providers, along with specimen collection services. These digital platforms streamline access to laboratory services, a growing trend in healthcare to improve patient engagement and operational efficiency. Further research on ValueRay can provide deeper insights into Labcorps financial performance and market position.
Headlines to watch out for
- Diagnostic testing volume directly impacts revenue growth
- Biopharma services contract awards drive segment performance
- Healthcare reimbursement rates influence profitability
- Regulatory changes in laboratory testing create compliance costs
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income: 876.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 0.59 > 1.0 |
| NWC/Revenue: 8.58% < 20% (prev 11.35%; Δ -2.77% < -1%) |
| CFO/TA 0.09 > 3% & CFO 1.64b > Net Income 876.5m |
| Net Debt (6.68b) to EBITDA (2.01b): 3.32 < 3 |
| Current Ratio: 1.42 > 1.5 & < 3 |
| Outstanding Shares: last quarter (83.2m) vs 12m ago -1.19% < -2% |
| Gross Margin: 28.24% > 18% (prev 0.28%; Δ 2796 % > 0.5%) |
| Asset Turnover: 75.88% > 50% (prev 70.78%; Δ 5.10% > 0%) |
| Interest Coverage Ratio: 5.94 > 6 (EBITDA TTM 2.01b / Interest Expense TTM 224.1m) |
Altman Z'' 3.37
| A: 0.07 (Total Current Assets 4.02b - Total Current Liabilities 2.82b) / Total Assets 18.39b |
| B: 0.47 (Retained Earnings 8.64b / Total Assets 18.39b) |
| C: 0.07 (EBIT TTM 1.33b / Avg Total Assets 18.39b) |
| D: 0.88 (Book Value of Equity 8.62b / Total Liabilities 9.76b) |
| Altman-Z'' Score: 3.37 = A |
Beneish M -2.98
| DSRI: 1.01 (Receivables 2.26b/2.10b, Revenue 13.95b/13.01b) |
| GMI: 0.99 (GM 28.24% / 27.86%) |
| AQI: 1.07 (AQ_t 0.61 / AQ_t-1 0.57) |
| SGI: 1.07 (Revenue 13.95b / 13.01b) |
| TATA: -0.04 (NI 876.5m - CFO 1.64b) / TA 18.39b) |
| Beneish M-Score: -2.98 (Cap -4..+1) = A |
What is the price of LH shares?
As of March 11, 2026, the stock is trading at USD 268.70 with a total of 510,592 shares traded.
Over the past week, the price has changed by -5.05%, over one month by -5.32%, over three months by +2.82% and over the past year by +11.25%.
Over the past week, the price has changed by -5.05%, over one month by -5.32%, over three months by +2.82% and over the past year by +11.25%.
Is LH a buy, sell or hold?
Laboratory of America has received a consensus analysts rating of 4.45.
Therefore, it is recommended to buy LH.
- StrongBuy: 13
- Buy: 3
- Hold: 4
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the LH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 307.6 | 14.5% |
| Analysts Target Price | 307.6 | 14.5% |
LH Fundamental Data Overview March 10, 2026
P/E Trailing = 25.7811
P/E Forward = 15.2207
P/S = 1.6024
P/B = 2.5779
P/EG = 0.9517
Revenue TTM = 13.95b USD
EBIT TTM = 1.33b USD
EBITDA TTM = 2.01b USD
Long Term Debt = 5.08b USD (from longTermDebt, last quarter)
Short Term Debt = 695.8m USD (from shortTermDebt, last quarter)
Debt = 7.21b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.68b USD (from netDebt column, last quarter)
Enterprise Value = 29.03b USD (22.36b + Debt 7.21b - CCE 532.3m)
Interest Coverage Ratio = 5.94 (Ebit TTM 1.33b / Interest Expense TTM 224.1m)
EV/FCF = 24.07x (Enterprise Value 29.03b / FCF TTM 1.21b)
FCF Yield = 4.15% (FCF TTM 1.21b / Enterprise Value 29.03b)
FCF Margin = 8.64% (FCF TTM 1.21b / Revenue TTM 13.95b)
Net Margin = 6.28% (Net Income TTM 876.5m / Revenue TTM 13.95b)
Gross Margin = 28.24% ((Revenue TTM 13.95b - Cost of Revenue TTM 10.01b) / Revenue TTM)
Gross Margin QoQ = 26.18% (prev 28.77%)
Tobins Q-Ratio = 1.58 (Enterprise Value 29.03b / Total Assets 18.39b)
Interest Expense / Debt = 0.76% (Interest Expense 55.0m / Debt 7.21b)
Taxrate = 13.48% (25.7m / 190.6m)
NOPAT = 1.15b (EBIT 1.33b * (1 - 13.48%))
Current Ratio = 1.42 (Total Current Assets 4.02b / Total Current Liabilities 2.82b)
Debt / Equity = 0.84 (Debt 7.21b / totalStockholderEquity, last quarter 8.62b)
Debt / EBITDA = 3.32 (Net Debt 6.68b / EBITDA 2.01b)
Debt / FCF = 5.54 (Net Debt 6.68b / FCF TTM 1.21b)
Total Stockholder Equity = 8.52b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.77% (Net Income 876.5m / Total Assets 18.39b)
RoE = 10.28% (Net Income TTM 876.5m / Total Stockholder Equity 8.52b)
RoCE = 9.78% (EBIT 1.33b / Capital Employed (Equity 8.52b + L.T.Debt 5.08b))
RoIC = 8.17% (NOPAT 1.15b / Invested Capital 14.10b)
WACC = 5.89% (E(22.36b)/V(29.56b) * Re(7.58%) + D(7.21b)/V(29.56b) * Rd(0.76%) * (1-Tc(0.13)))
Discount Rate = 7.58% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -1.01%
[DCF] Terminal Value 84.60% ; FCFF base≈1.16b ; Y1≈992.5m ; Y5≈766.8m
[DCF] Fair Price = 202.2 (EV 23.34b - Net Debt 6.68b = Equity 16.67b / Shares 82.4m; r=5.90% [WACC]; 5y FCF grow -17.70% → 2.90% )
EPS Correlation: -43.21 | EPS CAGR: -10.27% | SUE: 1.87 | # QB: 4
Revenue Correlation: 29.85 | Revenue CAGR: -2.73% | SUE: -1.21 | # QB: 0
EPS next Quarter (2026-06-30): EPS=4.74 | Chg7d=+0.019 | Chg30d=+0.116 | Revisions Net=+6 | Analysts=12
EPS current Year (2026-12-31): EPS=17.77 | Chg7d=+0.035 | Chg30d=+0.251 | Revisions Net=+11 | Growth EPS=+8.1% | Growth Revenue=+5.2%
EPS next Year (2027-12-31): EPS=19.27 | Chg7d=-0.008 | Chg30d=+0.077 | Revisions Net=+4 | Growth EPS=+8.5% | Growth Revenue=+4.8%
[Analyst] Revisions Ratio: +0.50 (9 Up / 3 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.1% (Discount Rate 7.9% - Earnings Yield 3.9%)
[Growth] Growth Spread = +0.7% (Analyst 4.8% - Implied 4.1%)
P/E Forward = 15.2207
P/S = 1.6024
P/B = 2.5779
P/EG = 0.9517
Revenue TTM = 13.95b USD
EBIT TTM = 1.33b USD
EBITDA TTM = 2.01b USD
Long Term Debt = 5.08b USD (from longTermDebt, last quarter)
Short Term Debt = 695.8m USD (from shortTermDebt, last quarter)
Debt = 7.21b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.68b USD (from netDebt column, last quarter)
Enterprise Value = 29.03b USD (22.36b + Debt 7.21b - CCE 532.3m)
Interest Coverage Ratio = 5.94 (Ebit TTM 1.33b / Interest Expense TTM 224.1m)
EV/FCF = 24.07x (Enterprise Value 29.03b / FCF TTM 1.21b)
FCF Yield = 4.15% (FCF TTM 1.21b / Enterprise Value 29.03b)
FCF Margin = 8.64% (FCF TTM 1.21b / Revenue TTM 13.95b)
Net Margin = 6.28% (Net Income TTM 876.5m / Revenue TTM 13.95b)
Gross Margin = 28.24% ((Revenue TTM 13.95b - Cost of Revenue TTM 10.01b) / Revenue TTM)
Gross Margin QoQ = 26.18% (prev 28.77%)
Tobins Q-Ratio = 1.58 (Enterprise Value 29.03b / Total Assets 18.39b)
Interest Expense / Debt = 0.76% (Interest Expense 55.0m / Debt 7.21b)
Taxrate = 13.48% (25.7m / 190.6m)
NOPAT = 1.15b (EBIT 1.33b * (1 - 13.48%))
Current Ratio = 1.42 (Total Current Assets 4.02b / Total Current Liabilities 2.82b)
Debt / Equity = 0.84 (Debt 7.21b / totalStockholderEquity, last quarter 8.62b)
Debt / EBITDA = 3.32 (Net Debt 6.68b / EBITDA 2.01b)
Debt / FCF = 5.54 (Net Debt 6.68b / FCF TTM 1.21b)
Total Stockholder Equity = 8.52b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.77% (Net Income 876.5m / Total Assets 18.39b)
RoE = 10.28% (Net Income TTM 876.5m / Total Stockholder Equity 8.52b)
RoCE = 9.78% (EBIT 1.33b / Capital Employed (Equity 8.52b + L.T.Debt 5.08b))
RoIC = 8.17% (NOPAT 1.15b / Invested Capital 14.10b)
WACC = 5.89% (E(22.36b)/V(29.56b) * Re(7.58%) + D(7.21b)/V(29.56b) * Rd(0.76%) * (1-Tc(0.13)))
Discount Rate = 7.58% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -1.01%
[DCF] Terminal Value 84.60% ; FCFF base≈1.16b ; Y1≈992.5m ; Y5≈766.8m
[DCF] Fair Price = 202.2 (EV 23.34b - Net Debt 6.68b = Equity 16.67b / Shares 82.4m; r=5.90% [WACC]; 5y FCF grow -17.70% → 2.90% )
EPS Correlation: -43.21 | EPS CAGR: -10.27% | SUE: 1.87 | # QB: 4
Revenue Correlation: 29.85 | Revenue CAGR: -2.73% | SUE: -1.21 | # QB: 0
EPS next Quarter (2026-06-30): EPS=4.74 | Chg7d=+0.019 | Chg30d=+0.116 | Revisions Net=+6 | Analysts=12
EPS current Year (2026-12-31): EPS=17.77 | Chg7d=+0.035 | Chg30d=+0.251 | Revisions Net=+11 | Growth EPS=+8.1% | Growth Revenue=+5.2%
EPS next Year (2027-12-31): EPS=19.27 | Chg7d=-0.008 | Chg30d=+0.077 | Revisions Net=+4 | Growth EPS=+8.5% | Growth Revenue=+4.8%
[Analyst] Revisions Ratio: +0.50 (9 Up / 3 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.1% (Discount Rate 7.9% - Earnings Yield 3.9%)
[Growth] Growth Spread = +0.7% (Analyst 4.8% - Implied 4.1%)